Pharmacopeia

Pharmacopeia, Inc. is a biopharmaceutical company dedicated to the discovery and development of therapeutic drugs to meet significant medical needs. Its internal project portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently in Phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; PS178990, a muscle-selective SARM agonist currently in clinical development. The company’s products also include PS031291, in preclinical development for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis, as well as a JAK3 inhibitor for T-cell and cytokine-mediated skin and eye diseases, such as psoriasis and dry eye disease.